glp-1 shortage news today november 2025 The class of medicines known as GLP-1s have transformed clinical practice and shifted public perception to view obesity as a chronic disease that merits medical management. Growing research is demonstrating that the glp-1 shortages news november 2025

Healthcare providers need to overcome barriers related to the shortage and mitigate undesired negative consequences from an inability of patients with type 2 diabetes mellitus to obtain GLP-1 receptor agonist therapies amid this global access challenge

(NIDDK) If I am not starving, that means I am not eating enough. Not necessarily

Its available within both Core+ and Med+, but only Med+ can provide clinicians and prescriptions through WeightWatchers Clinic

Ascendis Pharma A/S granted Novo Nordisk A/S exclusive global rights to its TransCon technology for the development, manufacturing, and commercialisation of Novo Nordisk products aimed at metabolic diseases, including obesity and type 2 diabetes, along with select cardiovascular applications